BGAM
PFE icon

Boussard & Gavaudan Asset Management’s Pfizer PFE Stock Holding History

Boussard & Gavaudan Asset Management’s Portfolio PFE Stock Details PFE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-7,828
Closed -$221K – 64
2014
Q2 		$221K Buy
+7,828
New +$223K 0.11% 101

Other funds holding PFE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Boussard & Gavaudan Asset Management's PFE Position: Q3 2014 in Review

Boussard & Gavaudan Asset Management sold out of Pfizer (PFE) in Q3 2014, closing a stake of 7,828 shares — an estimated $221K sold.

Boussard & Gavaudan Asset Management first reported a position in PFE in Q2 2014 and held it in 1 quarter. The position peaked at $221K in Q2 2014. 1,742 funds tracked by Wall St. Rank hold PFE as of Q3 2014.

  • Boussard & Gavaudan Asset Management reported no remaining Pfizer position as of Q3 2014 after selling out during the quarter.
  • Boussard & Gavaudan Asset Management sold 7,828 Pfizer shares in Q3 2014, an estimated $221K.
  • Boussard & Gavaudan Asset Management first reported a position in Pfizer in Q2 2014 and held it in 1 quarter.
  • Boussard & Gavaudan Asset Management's Pfizer position peaked at $221K in Q2 2014.
  • 1,742 funds tracked by Wall St. Rank held Pfizer as of Q3 2014.

Based on Boussard & Gavaudan Asset Management's 13F filing for Q3 2014.